Vivek Mehta Interview (audio)
23m
·
GRACEcast Radiation Oncology Audio
·
This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).
The episode Vivek Mehta Interview (audio) from the podcast GRACEcast Radiation Oncology Audio has a duration of
23:33. It was first published
More episodes from GRACEcast Radiation Oncology Audio
Refining Radiation Therapy for Lung Cancer, Part 6: Moving Radiation Developments into Metastatic Lung Cancer (audio)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.
Refining Radiation Therapy for Lung Cancer, Part 5: New Techniques (audio)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes new technologies that are improving the accuracy and safety of radiation for stage non-small cell lung cancer (NSCLC).
Refining Radiation Therapy for Lung Cancer, Part 4: Defining a Role for SBRT (audio)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, covers the benefits and limitations of stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC).
Refining Radiation Therapy for Lung Cancer, Part 3: Recent Successes and Open Questions (audio)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews recent successful experiences with stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer and reviews several open questions about this strategy.
Refining Radiation Therapy for Lung Cancer, Part 2: The Rationale for Stereotactic Body Radiation Therapy, by Dr. Vivek Mehta (audio)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes the ways to modulate the efficacy of radiation and explains why stereotactic body radiation therapy (SBRT) may be particularly effective for early lung cancer.